Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive TKC Transfer Combined With Chemotherapy for Advanced NSCLC
NCT04990063Phase 1Unknown
- Sponsor
- Su Haichuan
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Su Haichuan. Primary endpoint: Incidence of adverse events (AEs) and serious adverse events (SAEs) at 24 months. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04990063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990063.